8-K: SeaStar Medical Appoints David Green as Chief Financial Officer

SeaStar Medical has appointed David Green as its new Chief Financial Officer, effective January 10, 2024, while Caryl Baron transitions to Vice President of Finance.

Summary

• SeaStar Medical has appointed David Green as Chief Financial Officer, effective January 10, 2024.
• David Green will receive an annual base salary of $375,000 and is eligible for a 40% annual bonus based on personal and company performance.
• He will also receive 450,000 restricted stock units, vesting over 37 months.
• Green may receive additional cash and equity bonuses if the company completes financing transactions of $15,000,000 or more.
• Caryl Baron, the interim CFO since October 2022, will transition to Vice President of Finance.
• David Green has over 25 years of financial experience in the healthcare sector, including roles at Aytu BioPharma and Intarcia Therapeutics.
• The company is preparing for its first commercial launch of the Selected Cytopheretic Device Pediatric (SCD-PED) later this quarter.

Sentiment

Score: 8

Explanation: The document reflects a positive sentiment due to the appointment of an experienced CFO, the upcoming product launch, and the company's growth trajectory. However, the document also acknowledges risks associated with regulatory approvals and funding.

Positives

• The appointment of David Green brings a seasoned financial executive with over 25 years of experience in the healthcare sector.
• Green's experience includes roles at public medical device and pharmaceutical companies, which is valuable for SeaStar Medical's growth.
• The transition of Caryl Baron to Vice President of Finance ensures continuity and leverages her experience with the company.
• The company is progressing towards its first commercial launch of the SCD-PED product, indicating progress in its business plan.

Risks

• The company faces risks related to obtaining regulatory approval for its products.
• There is a risk that the company may not be able to raise sufficient capital to fund its operations and clinical trials.
• The company's success depends on the ability to develop and commercialize its products, which may be subject to delays.
• There is a risk that the company may not achieve or sustain profitability.
• The company is subject to risks related to third-party suppliers and manufacturers.
• The company faces potential product liability or regulatory lawsuits.
• There is a risk that the company may not be able to secure or protect its intellectual property.

Future Outlook

The company anticipates the first commercial launch of its SCD-PED product later this quarter. The company also has forward looking statements regarding the ability to obtain regulatory approval, raise sufficient capital, and achieve profitability.

Management Comments

• Eric Schlorff, CEO of SeaStar Medical, stated that David Green's financial experience will be highly valuable as they work to bring their solutions to those with hyperinflammation.
• Eric Schlorff thanked Caryl Baron for her service as interim CFO.
• David Green expressed excitement about joining the team and the potential of the company's technology.

Industry Context

The appointment of a seasoned CFO like David Green is a positive step for SeaStar Medical as it prepares for its first commercial launch. This move aligns with the company's growth phase and the need for strong financial leadership in the medical device sector.

Comparison to Industry Standards

• The compensation package for David Green, including a $375,000 base salary and potential 40% bonus, is competitive with similar executive roles in publicly traded medical device companies.
• The vesting schedule for the 450,000 restricted stock units, with 25% vesting on the first anniversary and the remainder over 36 months, is a standard practice in the industry.
• The potential for additional bonuses based on financing milestones is a common incentive structure used to align executive compensation with company performance and growth.
• The transition of the interim CFO to VP of Finance is a common practice to retain talent and ensure continuity.

Management Changes

Stakeholder Impact

• Shareholders may view the appointment of an experienced CFO positively, potentially increasing investor confidence.
• Employees may benefit from the company's growth and the launch of new products.
• Customers, particularly healthcare providers and patients, may benefit from the company's innovative therapies.
• Suppliers and creditors may see increased business opportunities as the company expands.

Next Steps

• The company will proceed with the commercial launch of the SCD-PED product later this quarter.
• The company will work towards completing financing transactions to trigger additional bonuses for David Green.
• The company will continue to develop and commercialize its cell-directed extracorporeal therapies.

Key Dates

Keywords

Chief Financial Officer, CFO, SeaStar Medical, David Green, Medical Device, Hyperinflammation, SCD-PED, Executive Appointment, Financial Officer, Healthcare